GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative that also shares the 3,4-methylenedioxyamphetamine pharmacophore. Unlike other similar drugs, GYKI 52895 is a selective dopamine reuptake inhibitor (DRI), which appears to have an atypical mode of action compared to other DRIs. Its DRI activity is shared by numerous addictive drugs including amphetamine and its derivatives (e.g. dextromethamphetamine), cocaine, and methylphenidate and its derivatives (e.g. ethylphenidate). However, dopaminergic drugs are also prone to producing emetic effects such as in the case of apomorphine.
{{Drugbox | Watchedfields = changed | verifiedrevid = 449582997 | IUPAC_name = 4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline | image = GYKI-52895.svg | image_class = skin-invert-image | width = 200px | image2 = GYKI-52895-3d.png | image_class2 = bg-transparent | width2 = 200px
| tradename = | legal_status =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).